Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose, Reduced Frequency Nivolumab in Unresectable or Metastatic Cancer
NCT07576725Phase 2Not yet recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2026
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), clear cell renal cell carcinoma (ccRCC), melanoma, squamous cell carcinoma (SCC), sponsored by Fred Hutchinson Cancer Center. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)clear cell renal cell carcinoma (ccRCC)melanomasquamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT07576725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576725.